Search
VXA-CoV2-1
go.drugbank.com/drugs/DB16433InvestigationalVXA-CoV2-1 is a non-replicating adenoviral vector-based oral tableted vaccine candidate that expresses a SARS-CoV-2 antigen and dsRNA adjuvant[L30493]. … This oral vaccine aims to induce immunogenicity through induction of potent serum neutralizing antibodies to the SARS-CoV-2 spike protein, induction of mucosal immune responses, and induction of T-cell
Revaprazan
go.drugbank.com/drugs/DB16308InvestigationalRevaprazan is under investigation in clinical trial NCT01750437 (Phase 2 Clinical Trial to Investigate the Safety, Tolerability and Efficacy of YH1885L in Patients With Non-erosive Reflux Disease(nerd)
Stannous chloride
go.drugbank.com/drugs/DB11056ApprovedTin reduces technetium-99m, the active radiological agent, allowing it to form a complex with phosphate-containing moeities [A32700].
AP103
go.drugbank.com/drugs/DB18234ExperimentalAP103 is a non-viral gene therapy that uses a delivery vector, HPAE (Highly Branched Poly β-Amino Ester), to deliver the correct collagen VII gene into skin cells.
Leriglitazone
go.drugbank.com/drugs/DB15021InvestigationalLeriglitazone is under investigation in clinical trial NCT03917225 (A Clinical Study to Evaluate the Effect of MIN-102 on the Progression of Friedreich's Ataxia in Male and Female Patients).
Embusartan
go.drugbank.com/drugs/DB19949ExperimentalThe usage of the INN stem '-sartan' in the name indicates that Embusartan is a angiotensin II receptor antagonist, antihypertensive (non-peptidic).
Categories: Agents Acting on the Renin-Angiotensin SystemDextromoramide
go.drugbank.com/drugs/DB01529ExperimentalIllicitAn opioid analgesic structurally related to methadone and used in the treatment of severe pain. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1070)
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromePX-478
go.drugbank.com/drugs/DB06082InvestigationalPX-478 was effective in models of both non-small cell lung cancer and small cell lung cancer that express HIF-1 alpha.
Gam-COVID-Vac
go.drugbank.com/drugs/DB15848InvestigationalGam-COVID-Vac was created by Gamaleya Research Institute of Epidemiology and MIcrobiology in Russia. … Preliminary results suggested that all participants developed antibodies to the SARS-CoV-2 glycoproteins with a good safety profile in both trials.